{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:52:23Z","timestamp":1785775943936,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004762.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000}}],"reference-count":138,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004762.pub3","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:55:02Z","timestamp":1744106102000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug treatment for myotonia"],"prefix":"10.1002","volume":"2025","author":[{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[{"name":"Queen Square Centre for Neuromuscular Diseases; The National Hospital for Neurology and Neurosurgery; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Trip","sequence":"additional","affiliation":[{"name":"Department of Neurology; Isala Hospital; Zwolle Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gea","family":"Drost","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery; University Medical Centre Groningen, University of Groningen; Groningen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina G","family":"Faber","sequence":"additional","affiliation":[{"name":"Department of Neurology; Maastricht University Medical Centre, Mental Health and Neuroscience Research Institute; Maastricht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Hanna","sequence":"additional","affiliation":[{"name":"Queen Square Centre for Neuromuscular Diseases; The National Hospital for Neurology and Neurosurgery; London UK"},{"name":"Department of Neuromuscular Diseases; University College London Queen Square Institute of Neurology; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Nevitt","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination; University of York; York UK"},{"name":"Department of Health Data Science; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinojini","family":"Vivekanandam","sequence":"additional","affiliation":[{"name":"Queen Square Centre for Neuromuscular Diseases; The National Hospital for Neurology and Neurosurgery; London UK"},{"name":"Department of Neuromuscular Diseases; University College London Queen Square Institute of Neurology; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD004762.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"issue":"9","key":"10.1002\/14651858.CD004762.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.40.9.1473","article-title":"Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial","volume":"40","author":"Antonini","year":"1990","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD004762.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.33.5.599-a","article-title":"The treatment of myotonia: evaluation of chronic oral taurine therapy","volume":"33","author":"Durelli","year":"1983","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jnnp.45.5.461","article-title":"A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy","volume":"45","author":"Finlay","year":"1982","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002060-198910000-00003","article-title":"A pilot controlled study of the use of imipramine to reduce myotonia","volume":"68","author":"Gascon","year":"1989","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/jnnp.50.2.199","article-title":"Nifedipine in the treatment of myotonia in myotonic dystrophy","volume":"50","author":"Grant","year":"1987","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/WNL.0000000000011002","article-title":"Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial","volume":"96","author":"Heatwole","year":"2021","journal-title":"Neurology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004762.pub3-BIB0009|cit9","first-page":"199","article-title":"Treatment of myotonia with mexiletine","volume":"9","author":"Kratz","year":"1986","journal-title":"Muscle & Nerve (Abstract)"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.1992.tb05103.x","article-title":"Treatment of myotonia with antiarrhythmic drugs","volume":"86","author":"Kwiecinski","year":"1992","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"10.1002\/14651858.CD004762.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1212\/WNL.16.8.831","article-title":"Trial of diazepam in myotonia \u2013 a controlled clinical trial","volume":"16","author":"Lewis","year":"1966","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/82.1.81","article-title":"The treatment of myotonia: a controlled clinical trial","volume":"82","author":"Leyburn","year":"1959","journal-title":"Brain"},{"issue":"18","key":"10.1002\/14651858.CD004762.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"issue":"18","key":"10.1002\/14651858.CD004762.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.17.4.359","article-title":"Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo","volume":"17","author":"Munsat","year":"1967","journal-title":"Neurology"},{"issue":"13","key":"10.1002\/14651858.CD004762.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"issue":"22","key":"10.1002\/14651858.CD004762.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD004762.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscular Disorders"},{"issue":"13","key":"10.1002\/14651858.CD004762.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/01.wnl.0000257825.29703.e8","article-title":"Efficacy of propafenone in paramyotonia congenita","volume":"68","author":"Alfonsi","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000004229","article-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","volume":"89","author":"Arnold","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2796.1990.tb00282.x","article-title":"Effect of sodium selenite and vitamin E treatment in myotonic dystrophy","volume":"228","author":"Backman","year":"1990","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1017\/S0317167100026305","article-title":"Treatment of paramyotonia congenita with acetazolamide","volume":"14","author":"Benstead","year":"1987","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00316381","article-title":"Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin","volume":"210","author":"Birnberger","year":"1975","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jnnp.46.6.587","article-title":"The depression of myotonic dystrophy: response to imipramine","volume":"46","author":"Brumback","year":"1983","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/WNF.0b013e3181ae5546","article-title":"Fluoxetine blocks myotonic runs and reverts abnormal surface electromyogram pattern in patients with myotonic dystrophy type 1","volume":"32","author":"Chisari","year":"2009","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004762.pub3-BIB0026|cit26","first-page":"193","article-title":"Beneficial response to a calcium channel antagonist in myotonic syndromes","volume":"34","author":"Cook","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410110305","article-title":"Taurine and hyperexcitable human muscle: effects of taurine on potassium-induced hyperexcitability of dystrophic myotonic and normal muscles","volume":"11","author":"Durelli","year":"1982","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jnnp.17.1.83","article-title":"The treatment of dystrophia myotonica with A.C.T.H","volume":"17","author":"Garai","year":"1954","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/78.1.81","article-title":"Procaine amide in the treatment of myotonia","volume":"78","author":"Geschwind","year":"1955","journal-title":"Brain"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0030|cit30","first-page":"133","article-title":"Effect of acetazolamide on myotonia","volume":"102","author":"Griggs","year":"1977","journal-title":"Transactions of the American Neurological Association"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ana.410030614","article-title":"Effects of acetazolamide on myotonia","volume":"3","author":"Griggs","year":"1978","journal-title":"Annals of Neurology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD004762.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.39.2.219","article-title":"Randomized controlled trial of testosterone in myotonic dystrophy","volume":"39","author":"Griggs","year":"1989","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0404.1978.tb05870.x","article-title":"Baclofen trial in six myotonic dystrophy patients","volume":"57","author":"Guilleminault","year":"1978","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archneurol.2010.227","article-title":"Open-label trial of recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1","volume":"68","author":"Heatwole","year":"2011","journal-title":"Archives of Neurology"},{"issue":"8732","key":"10.1002\/14651858.CD004762.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0140-6736(91)93342-7","article-title":"Response to treatment with antihistamines in a family with myotonia congenita","volume":"337","author":"Hughes","year":"1991","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mus.880170710","article-title":"Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy","volume":"17","author":"Jackson","year":"1994","journal-title":"Muscle and Nerve"},{"issue":"7869","key":"10.1002\/14651858.CD004762.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(74)90036-1","article-title":"Effect of baclofen on myotonia","volume":"1","author":"Karli","year":"1974","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.26372","article-title":"Open-label trial of ranolazine for the treatment of paramyotonia congenita","volume":"59","author":"Lorusso","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"10","key":"10.1002\/14651858.CD004762.pub3-BIB0039|cit39","first-page":"661","article-title":"A clinical trial of creatine monohydrate in muscular dystrophy patients","volume":"44","author":"Matsumura","year":"2004","journal-title":"Clinical Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00313863","article-title":"Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert","volume":"232","author":"Mielke","year":"1985","journal-title":"Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD004762.pub3-BIB0041|cit41","first-page":"983","article-title":"Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise","volume":"71","author":"Milner-Brown","year":"1990","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"8","key":"10.1002\/14651858.CD004762.pub3-BIB0042|cit42","first-page":"464","article-title":"Clinical and neurophysiological findings in serum controlled diphenylhydantoin application \u2013 considerations on myotonic dystrophy therapy","volume":"32","author":"M\u00fcller","year":"1980","journal-title":"Psychiatrie, Neurologie, und medizinische Psychologie"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.0954-6820.1986.tb03331.x","article-title":"Myotonic dystrophy treated with selenium and vitamin E","volume":"219","author":"Orndahl","year":"1986","journal-title":"Acta Medica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.1994.tb01061.x","article-title":"Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study","volume":"235","author":"Orndahl","year":"1994","journal-title":"Journal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0045|cit45","first-page":"591","article-title":"The treatment of myotonia with L-Dopa. Clinical and electromyographic study","volume":"78","author":"Pendefunda","year":"1974","journal-title":"Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/01.wnl.0000324257.35759.40","article-title":"Dehydroepiandrosterone for myotonic dystrophy type 1","volume":"71","author":"P\u00e9nisson-Besnier","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/jnnp.43.3.268","article-title":"Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide","volume":"43","author":"Ricker","year":"1980","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00313157","article-title":"Improved therapy of myotonia with the lidocaine derivative tocainide","volume":"222","author":"R\u00fcdel","year":"1980","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0049|cit49","first-page":"87","article-title":"Von Eulenberg's paramyotonia. A clinical study of restricted myotonia and episodic paralysis successfully controlled by chlorothiazide","volume":"89","author":"Samaha","year":"1964","journal-title":"Transactions of the American Neurological Association"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.WNL.0000044405.29988.E1","article-title":"Creatine monohydrate in DM2\/PROMM: a double-blind placebo controlled clinical study. Proximal myotonic myopathy","volume":"60","author":"Schneider-Gold","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0051|cit51","first-page":"113","article-title":"Carbamazepine versus diphenylhydantoin in the treatment of myotonia","volume":"22","author":"Sechi","year":"1983","journal-title":"European Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mus.880100209","article-title":"Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients","volume":"10","author":"Streib","year":"1987","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/WNL.51.2.586","article-title":"A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy","volume":"51","author":"Sugino","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mus.10527","article-title":"Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1","volume":"29","author":"Tarnopolsky","year":"2004","journal-title":"Muscle & Nerve"},{"issue":"12","key":"10.1002\/14651858.CD004762.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1210\/jcem.80.12.8530624","article-title":"Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy \u2013 a clinical research center study","volume":"80","author":"Vlachopapadopoulou","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD004762.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00415-002-0923-x","article-title":"Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study","volume":"249","author":"Walter","year":"2002","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0057|cit57","unstructured":"Efficacy and safety of tideglusib in congenital myotonic dystrophy https:\/\/clinicaltrials.gov\/study\/NCT03692312"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0058|cit58","unstructured":"Open-label extension study in paediatric patients who have completed the MEX-NM-301 study https:\/\/clinicaltrials.gov\/study\/NCT04622553"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0059|cit59","unstructured":"Open label study in adolescents and children with myotonic disorders https:\/\/clinicaltrials.gov\/study\/NCT04624750"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0060|cit60","unstructured":"MExiletine versus lamotrigine in Non-Dystrophic myotonia (MEND) https:\/\/clinicaltrials.gov\/study\/NCT05017155"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0061|cit61","unstructured":"Treatment of myotonia \u2013 lamotrigine versus namuscla https:\/\/clinicaltrials.gov\/study\/NCT05639257"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"102329","DOI":"10.1016\/j.coph.2022.102329","article-title":"Drug repurposing in skeletal muscle ion channelopathies","volume":"68","author":"Altamura","year":"2023","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0063|cit63","volume-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1987"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.35.4.293","article-title":"Myotonia congenita in northern Finland: an epidemiological and genetic study","volume":"35","author":"Baumann","year":"1998","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0065|cit65","volume-title":"Paramyotonia Congenita (Eulenburg)","author":"Becker","year":"1970"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0066|cit66","volume-title":"Myotonia Congenita and Syndromes Associated with Myotonia. Clinical-Genetic Studies of the Nondystrophic Myotonias","author":"Becker","year":"1977"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.20235","article-title":"Myocytes from congenital myotonic dystrophy display abnormal Na+ channel activities","volume":"31","author":"Bernareggi","year":"2005","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2174\/138945009789735138","article-title":"The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers","volume":"10","author":"Bourin","year":"2009","journal-title":"Current Drug Targets"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0069|cit69","first-page":"47","volume-title":"Handbook of Experimental Pharmacology: Adrenergic Activators and Inhibitors, Part II","volume":"54\/II","author":"Bowman","year":"1981"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0070|cit70","volume-title":"Statistical Methods in Cancer Research: the Analysis of Case-Control Studies","volume":"I","author":"Breslow","year":"1980"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0071|cit71","first-page":"385","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member","volume":"69","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2660(08)00804-3","article-title":"Therapeutic approaches to ion channel diseases","volume":"64","author":"Camerino","year":"2008","journal-title":"Advances in Genetics"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1651-2227.1992.tb12271.x","article-title":"Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine","volume":"81","author":"Ceccarelli","year":"1992","journal-title":"Acta Paediatrica"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","article-title":"Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing","volume":"10","author":"Charlet","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.nurt.2008.09.001","article-title":"Treatment of neuromuscular channelopathies: current concepts and future prospects","volume":"5","author":"Cleland","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01629597","article-title":"Familial atrophic myotonia","volume":"45","author":"C\u00fcrschmann","year":"1912","journal-title":"Deutsche Zeitschrift f\u00fcr Nervenheilk\u00fcnde"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0077|cit77","first-page":"270","article-title":"Effects of tocainide on normal and myotonic mammalian skeletal muscle","volume":"29","author":"Dengler","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","article-title":"Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy","volume":"69","author":"Desaphy","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JND-200582","article-title":"Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/brain\/124.2.352","article-title":"Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: a high density surface EMG study","volume":"124","author":"Drost","year":"2001","journal-title":"Brain"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases \u2013 a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscular Disorders"},{"issue":"4983","key":"10.1002\/14651858.CD004762.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.2173143","article-title":"Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene","volume":"250","author":"Fontaine","year":"1990","journal-title":"Science"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0098-2997(97)00050-2","article-title":"Diseases caused by voltage-gated ion channels","volume":"18","author":"Fontaine","year":"1997","journal-title":"Molecular Aspects of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-510X(74)90060-4","article-title":"The Schwartz-Jampel syndrome. Its clinical, physiological and histological expressions","volume":"22","author":"Layzer","year":"1974","journal-title":"Journal of the Neurological Sciences"},{"issue":"8","key":"10.1002\/14651858.CD004762.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.880140811","article-title":"Altered Na+ channel activity and reduced Cl- conductance cause hyperexcitability in recessive generalized myotonia (Becker)","volume":"14","author":"Franke","year":"1991","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/ng0493-305","article-title":"Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita)","volume":"3","author":"Crackower","year":"1993","journal-title":"Nature Genetics"},{"issue":"9-10","key":"10.1002\/14651858.CD004762.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nmd.2005.07.002","article-title":"Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist","volume":"15","author":"Hammar\u00e9n","year":"2005","journal-title":"Neuromuscular Disorders"},{"issue":"8802","key":"10.1002\/14651858.CD004762.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0140-6736(92)90729-M","article-title":"Unstable DNA sequence in myotonic dystrophy","volume":"339","author":"Harley","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0090|cit90","first-page":"47","volume-title":"Myotonic Dystrophy","author":"Harper","year":"2001"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oso\/9780198527824.003.0001","volume-title":"Myotonic Dystrophy","author":"Harper","year":"2004"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0093|cit93","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0094|cit94","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"16","key":"10.1002\/14651858.CD004762.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"issue":"Pt 3","key":"10.1002\/14651858.CD004762.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/112.3.779","article-title":"Anticipation in myotonic dystrophy: fact or fiction?","volume":"112","author":"Howeler","year":"1989","journal-title":"Brain"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0097|cit97","volume-title":"Channelopathies of the Nervous System","author":"Jurkat-Rott","year":"2001"},{"issue":"5071","key":"10.1002\/14651858.CD004762.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1379744","article-title":"The skeletal muscle chloride channel in dominant and recessive human myotonia","volume":"257","author":"Koch","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0099|cit99","first-page":"49","article-title":"Value of mexiletine in the treatment of Thomsen-Becker myotonia","volume":"43","author":"Leheup","year":"1986","journal-title":"Archives Fran\u00e7aises de P\u00e9diatrie"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.880100414","article-title":"Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH","volume":"10","author":"Lehmann-Horn","year":"1987","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mus.880100709","article-title":"Membrane defects in paramyotonia congenita (Eulenburg)","volume":"10","author":"Lehmann-Horn","year":"1987","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0102|cit102","first-page":"1303","volume-title":"Myology","author":"Lehmann-Horn","year":"1994"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0103|cit103","first-page":"533","volume-title":"Handbook of Clinical Neurology","author":"Lipicky","year":"1979"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000118206.49652.A3","article-title":"Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1","volume":"62","author":"Logigian","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mus.20339","article-title":"Quantitative analysis of the \"warm-up\" phenomenon in myotonic dystrophy type 1","volume":"32","author":"Logigian","year":"2005","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pediatrneurol.2014.05.027","article-title":"Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report","volume":"51","author":"Markhorst","year":"2014","journal-title":"Paediatric Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004762.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s100720070009","article-title":"Therapy in myotonic disorders and in muscle channelopathies","volume":"21","author":"Meola","year":"2000","journal-title":"Journal of the Neurological Sciences"},{"issue":"5 Pt 2","key":"10.1002\/14651858.CD004762.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0035-3787(04)71007-3","article-title":"Treatment in myotonia and periodic paralysis","volume":"160","author":"Meola","year":"2004","journal-title":"Revue Neurologique"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0960-8966(95)00036-4","article-title":"Proximal myotonic myopathy: mini review of a recently delineated clinical disorder","volume":"6","year":"1996","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0111|cit111","first-page":"665","article-title":"Myotonia with muscular weakness corrected by exercise: the therapeutic effect of mexiletine","volume":"139","author":"Pouget","year":"1983","journal-title":"Revue Neurologique"},{"issue":"8","key":"10.1002\/14651858.CD004762.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.44.8.1500","article-title":"Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalemic periodic paralysis","volume":"44","author":"Pt\u00e1cek","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0002-9343(98)00123-5","article-title":"The familial periodic paralyses and nondystrophic myotonias","volume":"105","author":"Pt\u00e1cek","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00312881","article-title":"Transient muscular weakness in severe recessive myotonia congenita. Improvement of isometric muscle force by drugs relieving myotomic stiffness","volume":"218","author":"Ricker","year":"1978","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s004150050359","article-title":"Myotonic dystrophy and proximal myotonic myopathy","volume":"246","author":"Ricker","year":"1999","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ana.410420520","article-title":"A novel muscle sodium channel mutation causes painful congenital myotonia","volume":"42","author":"Rosenfeld","year":"1997","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004762.pub3-BIB0117|cit117","first-page":"413","article-title":"Electrophysiological evaluation of congenital myotonia","volume":"25","author":"Rossi","year":"1985","journal-title":"Electromyography and Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0118|cit118","first-page":"1291","volume-title":"Myology","author":"R\u00fcdel","year":"1994"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004762.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1007\/s100720070012","article-title":"Quantitative myotonia assessment: an experimental protocol","volume":"21","author":"Sansone","year":"2000","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0120|cit120","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ajh.2830270413","article-title":"Procainamide-associated pancytopenia","volume":"27","author":"Shields","year":"1988","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.1987.00370030196040","article-title":"Tocainide-induced reversible agranulocytosis and anemia","volume":"147","author":"Soff","year":"1987","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/mus.22007","article-title":"An interactive voice response diary for patients with non-dystrophic myotonia","volume":"44","author":"Statland","year":"2011","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF01649715","article-title":"[Ein neuer fall von atrophischer myotonie: ein nachtag zu meiner arbeit in Bild 37]","volume":"39","author":"Steinert","year":"1910","journal-title":"Deutsche Zeitschrift f\u00fcr Nervenheilk\u00fcnde"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0125|cit125","unstructured":"Sterne J Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"5","key":"10.1002\/14651858.CD004762.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ana.410190515","article-title":"Successful treatment with tocainide of recessive generalized congenital myotonia","volume":"19","author":"Streib","year":"1986","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD004762.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurology"},{"issue":"11","key":"10.1002\/14651858.CD004762.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/jnnp-2017-317615","article-title":"Successful long-term therapy with flecainide in a family with paramyotonia congenita","volume":"89","author":"Terracciano","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/BF02164912","article-title":"[Tonische krampfe in willkurlich beweglichen muskeln in folge von erebter psychischer disposition (Ataxia muscularis?)]","volume":"6","author":"Thomsen","year":"1876","journal-title":"Archiv f\u00fcr Psychiatrie und Nervenkrankheiten"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1093\/brain\/awt133","article-title":"Non-dystrophic myotonia: prospective study of objective and patient reported outcomes","volume":"136","author":"Trivedi","year":"2013","journal-title":"Brain"},{"issue":"4","key":"10.1002\/14651858.CD004762.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp.2008.158261","article-title":"The myotonic dystrophies: diagnosis and management","volume":"81","author":"Turner","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ncl.2020.04.003","article-title":"Skeletal muscle channelopathies","volume":"38","author":"Vivekanandam","year":"2020","journal-title":"Neurologic Clinics"},{"issue":"7","key":"10.1002\/14651858.CD004762.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14737159.2020.1782195","article-title":"Improving genetic diagnostics of skeletal muscle channelopathies","volume":"20","author":"Vivekanandam","year":"2020","journal-title":"Expert Review of Molecular Diagnostics"},{"issue":"3","key":"10.1002\/14651858.CD004762.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nmd.2023.01.007","article-title":"Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing","volume":"33","author":"Vivekanandam","year":"2023","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1474-4422(24)00320-X","article-title":"Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial","volume":"23","author":"Vivekanandam","year":"2024","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD004762.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurpsyc.1936.02260080154011","article-title":"Quinine: an effective form of treatment of myotonia","volume":"36","author":"Wolf","year":"1936","journal-title":"Archives of Neurology and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004762.pub3-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004762","article-title":"Drug treatment for myotonia","author":"Trip","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004762.pub3-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004762.pub2","article-title":"Drug treatment for myotonia","author":"Trip","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:23:31Z","timestamp":1785774211000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004762.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":138,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004762.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}